A substantial proportion of computed tomographic pulmonary angiography (CTPA) results are degraded by patientrelated and technical factors, yielding a limited negative interpretation, which qualifies the definitive exclusion of pulmonary embolism. This leads to diagnostic uncertainty and may affect patient management. A multicenter randomized clinical trial of CTPA vs ventilation-perfusion scintigraphy considered CTPA results negative if no pulmonary embolism was demonstrated to the lobar level.
itly questioned the clinical relevance of small pulmonary emboli, 2,3 and there is growing concern that pulmonary embolism is overdiagnosed on CTPA. 4, 5 We hypothesized that a limited negative CTPA result portends similar clinical outcomes to a definitively negative result; thus, emphasis on examination limitations may, in fact, be detrimental.
Methods | This retrospective cohort study was approved by the institutional review board of the Montefiore Medical Center, which waived written informed consent. Included were all adults with suspected pulmonary embolism who underwent CTPA from July 1, 2011 , through June 30, 2012 , at the 3 emergency departments or inpatient sites of Montefiore Medical Center, Bronx, New York. We defined a limited negative CTPA result as one that reported no pulmonary embolism but also explicitly stated a limitation or qualification in the report impression. The primary outcome was 90-day venous thromboembolism incidence, a measure of the false-negative rate. Secondary outcomes were additional imaging, initiation of anticoagulation treatment, and bleeding complications.
Results | The study population comprised 2553 patients with mean (SD) age 55 (18) years, 66% women and 85% ethnic minorities. A total of 264 CTPA results (10%) were positive; 1663 (65%) were definitively negative; 569 (22%) were limited negative; and 57 (2%) were nondiagnostic for pulmonary embolism. In all, 25% of negative CTPA results (569 of 2232) were limited negative. Patients with limited negative CTPA results were more similar to patients with definitely negative results than they were to patients with positive results in their baseline characteristics and outcomes ( Table 1) .
The false-negative rate (90-day venous thromboembolism incidence) for patients with a limited negative CTPA re- Table 2) . Patients with limited negative vs definitively negative CTPA results had more additional imaging with ventilationperfusion scintigraphy (OR, 4.30; 95% CI, 1.83-10.11) and initiation of anticoagulation treatment (OR, 1.47; 95% CI, 1.17-1.87). There was a trend toward increased bleeding events (OR, 1.62; 95% CI, 0.98-2.69) in patients with limited vs definitively negative CTPA results. Discussion | At the population level, pulmonary embolism diagnosis has essentially doubled since CTPA replaced ventilation-perfusion scanning as the dominant imaging modality for suspected pulmonary embolism in the United States without accompanying changes in risk factors or mortality, but with an increase in bleeding complications. 4, 5 Patients diagnosed with pulmonary embolism by CTPA have a less severe disease spectrum than those diagnosed with scintigraphy and only half the odds of death.
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The present study demonstrates that patients with limited negative CTPA results in which small emboli cannot be excluded have similar outcomes to those with definitively negative studies. Further diagnostic testing or initiation of anticoagulation therapy is likely unnecessary in a substantial proportion of these patients, and careful consideration of the pretest probability is warranted.
Limitations of this study include its retrospective cohort and its single health system design with the inherent potential for unmeasured confounders, underreporting, and uncaptured events. However, these limitations are unlikely to create a systematic bias.
In conclusion, patients with limited negative CTPA results are indistinguishable from those with definitively negative results in false-negative rate (90-day venous thromboembolism incidence). These patients are more likely to be reimaged with ventilation-perfusion scanning and anticoagulated. Physicians have grown accustomed to advanced CT technology with submillimeter resolution such that a "limited" study often reflects only a minor deficiency in the usual superb image quality. A limited negative CTPA result should not be automatically interpreted as an indication of clinical uncertainty because the question of "clinically relevant" pulmonary embolism has most likely already been answered. 
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Association of Amiodarone Use With Acute Pancreatitis in Patients With Atrial Fibrillation: A Nested Case-Control Study
Amiodarone hydrochloride is an antiarrhythmic drug frequently used in the treatment of atrial fibrillation (AF). Isolated reports 1-3 have suggested that use of amiodarone may cause acute pancreatitis. To our knowledge, this potential adverse effect of amiodarone has not been explored in large studies. We assessed whether use of amiodarone or other antiarrhythmic drugs indicated for AF management is associated with developing acute pancreatitis in a large US population.
Methods | We conducted a nested case-control study using the Truven Health MarketScan Commercial and MarketScan Medicare Supplemental Databases for January 1, 2007, through December 31, 2012. These databases include health insurance claims that span all levels of care (inpatient and outpatient services, outpatient pharmacy services) and enrollment data from employers and health plans across the United States that provide private coverage for employees, their spouses, and their dependents and for individuals and their dependents with Medicare supplemental coverage. All patient information was Health Insurance Portability and Accountability Act compliant, deidentified, commercially available secondary data; therefore, the institutional review board at the University of Minnesota deemed this analysis exempt from review.
Case patients were patients with nonvalvular AF (NVAF) admitted to the hospital with a primary diagnosis of acute pancreatitis during the study period (International Classification of Diseases, Ninth Revision, Clinical Modification code 577.0) . Five control patients with NVAF were matched with each case patient by sex, year of birth, and MarketScan enrollment date selected from individuals enrolled at the time of the pancreatitis hospitalization (index date). Information on use of amiodarone, other medications, and comorbidities before the index date for case and control patients was obtained. We used multivariable conditional logistic regression to estimate odds ratios (ORs) and 95% CIs of acute pancreatitis by use of amiodarone and other antiarrhythmic drugs (each using separate regression models) and time since initiation and cumulative use of amiodarone, adjusting for confounders ( 
